Poziotinib

Poziotinib is an investigational drug not approved by the FDA.


Poziotinib is an investigational, orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations.

> To read the latest news about poziotinib, or to watch a video on its mechanism, click here.

Poziotinib is designed to be small and flexible. HER2

Poziotinib is an investigational drug not approved by the FDA.


In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death.

More About Poziotinib

Breast Cancer
SPI-POZ-201 (Phase 2): HER2+ Metastatic Breast Cancer

Latest News on Poziotinib